Genetic Testing for Facioscapulohumeral Muscular Dystrophy

**Policy**

Genetic testing for facioscapulohumeral muscular dystrophy may be considered **medically necessary** to confirm a diagnosis in a patient with clinical signs of the disease. (see Policy Guidelines)

Genetic testing for facioscapulohumeral muscular dystrophy is considered **investigational** for all other indications.

**Related Policies**

None

**Policy Guidelines**

FSHD is typically suspected in an individual with the following: weakness that predominantly involves the facial, scapular stabilizer, and foot dorsiflexor muscles without associated ocular or bulbar muscle weakness, and age of onset usually by 20 years of age (although mildly affected individuals show signs at a later age and some remain asymptomatic).

**Testing Strategy**

Because 95% of cases of FSHD are FSHD1, genetic testing for FSHD should begin with testing for contraction mutation in the macrosatellite repeat D4Z4 on chromosome 4q35 using Southern blot analysis. Depending on the index of suspicion for FSHD, if FSHD1 testing is negative, testing for FSHD2, including D4Z4 methylation analysis and testing of the SMCHD1 gene, could be considered.

**Coding**

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81404</td>
<td>Molecular pathology procedure, Level 5 (e.g., analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic</td>
</tr>
</tbody>
</table>
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disease that typically presents before the age of 20 years with weakness of the facial muscles and the scapular stabilizer muscles. The clinical course is usually of slowly progressive weakness, although the severity is highly variable, and atypical presentations occur. Genetic testing for FSHD can confirm the diagnosis.

**Description of the Disease**
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common muscular dystrophy and involves progressive weakness and wasting of the facial muscles (facio), and shoulder and upper arm (scapulohumeral) muscles. The weakness is often most evident in the muscles of the face, resulting in difficulty smiling and whistling, and reduced facial expression. The weakness in the shoulder muscles causes the scapula to protrude from the back ("winging of the scapula"). The muscles are typically affected asymmetrically, and with progression, the lower extremities, both proximal and distal, become involved. (1) The severity of the disease is highly variable, ranging from mildly affected, asymptomatic individuals to severely affected individuals, with approximately 20% of patients eventually requiring a wheelchair. Nonmuscular manifestations include retinal vascular abnormalities that can result in significant loss of vision; however, only about 1% of patients with FSHD experience visual acuity loss. (1) Most people with FSHD will eventually develop high-frequency hearing loss, which is usually not noticeable and only detected by audiogram. FSHD usually presents between the ages of 6 and 20 years, and life expectancy is not shortened. It is estimated that 4 to 5 people per 100,000 population have FSHD. FSHD affects males and females equally.

**Clinical diagnosis of FSHD**
FSHD has a characteristic distribution of muscle involvement that often can lead to targeted genetic testing without the need for a muscle biopsy. (2) However, atypical presentations have been reported, which include scapulohumeral dystrophy with facial sparing. (3,4) A retrospective review of an academic center database of the period 1996 to 2011 determined that, of 139 genetically confirmed FSHD cases, 7 had atypical disease, including late age of onset of disease, focal weakness, and dyspnea. (5)

Electromyography (EMG) and muscle biopsy to confirm the clinical diagnosis of FSHD has largely been supplanted by genetic testing. EMG usually shows mild myopathic changes, and muscle biopsy most often shows nonspecific chronic myopathic changes.

**Genetics of FSHD**
FSHD is likely to be caused by inappropriate expression of the gene DUX4 in muscle cells. DUX4 is a double homeobox-containing gene (a homeobox gene being one in a large family of genes that direct the formation of many body structures during early embryonic development). DUX4 lies in the macrosatellite repeat D4Z4, which is on chromosome 4q35. D4Z4 has a length of 11 to 100 repeat units on normal alleles. The most common form of FSHD (95%) is designated FSHD1, and these individuals have a D4Z4 allele of between 1 and 10 repeat units. (3) There is no absolute linear and inverse correlation between residual repeat size and disease severity and onset; however, patients with repeat arrays of 1 to 3 units usually have an infantile onset and rapid progression. (1)

The remaining 5% of patients who do not have FSHD1 are designated as FSHD2, which is clinically indistinguishable from FSHD1. Patients with FSHD2 show loss of DNA methylation and heterochromatin markers at the D4Z4 repeat that are similar to patients with D4Z4 contractions (FSHD1), suggesting that a change in D4Z4 chromatin structure unifies FSHD1 and FSHD2. Mutations in the SMCHD1 gene on chromosome 18, which encodes a protein known as structural maintenance of chromosomes flexible hinge domain containing 1, have been associated with FSHD2. Reductions in SMCHD1 gene product levels have been associated with D4Z4 contraction-independent DUX4 expression, suggesting that SMCHD1 acts as an epigenetic modifier of the D4Z4 allele. (6) SMCHD1 has also been identified as a possible modifier of disease severity in patients with FSHD1. (7)
FSHD is inherited in an autosomal dominant manner. Approximately 70% to 90% of individuals inherit the disease-causing deletion from a parent, and 10% to 30% have FSHD as a result of a de novo deletion. (3)

**Treatment of FSHD**

There is currently no treatment or prevention of symptoms of FSHD, and clinical management is directed at surveillance to identify possible FSHD-related complications, such as hearing loss, and to improve quality of life (e.g., assist devices, physical therapy, orthoses to improve mobility and prevent falls).

**Commercially Available Testing for FSHD**

The methodology for testing for FSHD1 uses pulsed field gel electrophoresis and Southern blot to detect deletions on chromosome 4q35.

Laboratories that offer FSHD1 testing include Athena Diagnostics and the University of Iowa Diagnostic Laboratories.

At least one commercial laboratory was identified that offers testing for FSHD2 through sequencing of the SMCHD1 gene via bidirectional Sanger sequencing (Prevention Genetics, Marshfield, WI). Prevention Genetics also offers testing for FSHD2 through sequencing of the SMCHD1 gene by next generation sequencing as part of a panel test for limb-girdle muscular dystrophy.

**Regulatory Status**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general standards of the Clinical Improvement Act (CLIA). Genetic testing for FSHD is available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of these tests.

**Scope**

Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

**Benefit Application**

N/A

**Rationale**

This evidence review was created in August 2013 and updated periodically with literature reviews, most recently through July 7, 2015. Literature that describes the analytic validity, clinical validity, and clinical utility of testing for facioscapulohumeral muscular dystrophy (FSHD) was sought (see Appendix Table 1 for genetic testing categories).
Analytic Validity
Analytic validity is the technical accuracy of the test in detecting a mutation that is present or in excluding a mutation that is absent.

According to one laboratory, Southern blotting diagnostic methods enable the identification of FSHD1 in about 95% of cases. (8)

No studies that assessed the analytic validity of SMCHD1 gene testing were identified.

Clinical Validity
Clinical validity is the diagnostic performance of the test (sensitivity, specificity, positive and negative predictive values) in detecting clinical disease.

According to a large reference laboratory, the identification of a characteristic 4q35 deletion is more than 90% specific for the disease. (9) However, several studies have identified patients with no clinical signs of FSHD who have characteristic D4Z4 contractures, which has prompted the hypothesis that FSHD occurs only when the D4Z4 contracture occurs in a characteristic "permissive" background. (10)

There are reports of a correlation between the degree of the mutation of the D4Z4 locus and the age at onset of symptoms, age at loss of ambulation, and muscle strength, as measured by quantitative isometric myometry. Some reports in the literature describe individuals with a large contraction of the D4Z4 locus having earlier-onset disease and more rapid progression than those with smaller contractions of the D4Z4 locus, although other reports have not been able to confirm a correlation between disease severity and degree of D4Z4 contraction mutations. (1)

On average, de novo mutations are associated with larger contractions of D4Z4 compared with the degree of D4Z4 contraction mutations observed segregating in families, and individuals with de novo mutations tend to have findings at the more severe end of the phenotypic spectrum. (3)

No studies that assessed clinical validity of SMCHD1 gene testing were identified.

Clinical utility how the results of the diagnostic test will be used to change management of the patient and whether these changes in management lead to clinically important improvements in health outcomes.

Testing in individuals with suspected FSHD. The clinical utility for patients with suspected FSHD depends on the ability of genetic testing to make a definitive diagnosis and for that diagnosis to lead to management changes that improve outcomes.

Several studies suggest that the size of the D4Z4 repeat contraction is associated with differences in patients’ outcomes. Lutz et al conducted a retrospective analysis of 59 patients with FSHD seen at a single institution to evaluate the relationship between the D4Z4 repeat size and progression of hearing loss. (11) Eleven of the 59 patients evaluated had hearing loss that was not attributable to another cause. Truncated D4Z4 (1-10 D4Z4 repeats) was evaluated by the size of EcoRI or EcoRI/BlnI fragment, with an EcoRI fragment of less than 38 kB or an EcoRI/BlnI fragment of less than 35 kg corresponding to 1 to 10 D4Z4 repeats. There was a statistically significant negative association between hearing loss and fragment size in a simple logistic regression model (p=0.021). Six of the 11 patients with hearing loss had a history of hearing loss progression.

In a retrospective analysis of a cohort of patients with FSHD1 enrolled in the National Registry of FSHD Patients and Family Members, Statland et al. evaluated the association between patient characteristics, including size of the D4Z4 contraction, and FSHD-related outcomes. (12) Three hundred thirteen clinically affected participants with D4Z4 contractions of 38 kB or less were included. Those with D4Z4 contractions of 18 kg or less started using wheelchairs earlier than those with contractions from 19 to 28 kb (24.1 years vs 48.1 years, p<0.001) or those with contractions of greater than 38 kb (58.6 years, p<0.001).

There is no direct evidence for the clinical utility of genetic testing in these patients, as no studies were identified that described how a molecular diagnosis of FSHD changed patient management. However, for patients who are diagnosed with FSHD by identifying a D4Z4 contraction mutation, the clinical utility of molecular genetic testing for
FSHD includes:

- Establishing the diagnosis and initiating/directing treatment, such as evaluation for physical therapy and the need for assistive devices, assessment for hearing loss, ophthalmologic examination for the presence of retinal telangiectasias and continued ophthalmologic surveillance, and possible orthopedic intervention.
- Distinguishing from other disorders that are similar clinically to FSHD, especially the limb-girdle muscular dystrophies and scapuloperoneal muscular dystrophy syndromes.
- Avoidance of a muscle biopsy in most cases.

Treatment after a confirmed diagnosis of FSHD includes physical therapy and rehabilitation, exercise, pain management, ventilator support for those with hypoventilation, therapy for hearing loss, orthopedic intervention (ankle/foot orthoses; surgical fixation of the scapula to the chest wall to improve range of motion) and ophthalmologic management including lubricants or taping the eyes shut at night for exposure keratitis.

For those with a confirmed diagnosis of FSHD, the following surveillance applies (3,13):

- Regular assessment of pain
- Routine screening for hypoventilation in those with moderate to severe disease, and yearly forced vital capacity measurements for all affected individuals who are wheelchair bound, have pelvic girdle weakness and superimposed pulmonary disease, and/or have moderate to severe kyphoscoliosis, lumbar hyperlordosis, or chest wall deformities.
- Hearing loss assessment in children as routinely performed as part of school-based testing. In severe infantile onset forms of FSHD, hearing screens are important as hearing loss can result in delayed language acquisition. Adults should have a formal hearing evaluation based on symptoms.
- Annual dilated ophthalmoscopy in childhood is indicated. In adults, a dilated retinal exam should be performed at the time of diagnosis, and if vascular disease is absent, follow-up exams are only necessary if visual symptoms develop.

Testing of family members with individuals with FSHD. Most individuals diagnosed with FSHD have a parent with clinical findings of FSHD and one D4Z4 allele with a contraction mutation (70-90% of individuals with FSHD), although 10% to 30% of probands with FSHD have the disorder as a result of a D4Z4 de novo contraction mutation. (3) Evaluation of at-risk relatives may determine that they may be affected but escaped previous diagnosis because of a milder phenotypic presentation. In 2013, Ricci et al. evaluated the D4Z4 site in 367 relatives of 163 FSHD index cases who carried D4Z4 “alleles of reduced size” of 8 or less repeating units. (10) Among relatives, a D4Z4 “alleles of reduced size” with 1 to 3 repeating units and 4 to 6 repeating units was identified in 42 and 133 subjects, respectively. Of those relatives with 1 to 3 repeating units, about 40% demonstrated severe muscle symptoms by age 30, while none of those with 4 or more repeating units had severe symptoms in that age range.

However, for this population, no evidence was identified that compared outcomes in family members tested for genetic mutations with family members not tested for genetic mutations, and conclusions cannot be made on whether genetic testing of asymptomatic family members of a patient with known FSHD improves outcomes. In contrast to patients with diagnosed FSHD, there are no established treatment guidelines or follow-up guidelines for at-risk relatives.

Section Summary: Clinical Utility
D4Z4 contractions are associated with FSHD, and the size of the contracture is associated with more severe symptoms. Although there is no direct evidence for the clinical utility of genetic testing for patients with suspected FSHD, as no studies were identified that described how a molecular diagnosis of FSHD changed patient management, a chain of evidence supports the use of D4Z4 contraction mutation testing for suspected FSHD to establish a diagnosis and initiate therapies consistent with appropriate guidelines and avoid a muscle biopsy in most cases.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 1.
Enrollment Date
Ongoing NCT01437345 A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset Facioscapulohumeral Muscular Dystrophy 50 Mar 2015
NCT01970735 Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2 100 Oct 2016

Summary of Evidence
The evidence for genetic testing in patients who have clinical signs of FSHD syndrome is generally lacking. Relevant outcomes are test accuracy, test validity, morbid events, functional outcomes, quality of life, and resource utilization. Test accuracy and validity have been reported to be high. A definitive diagnosis may end the need for additional testing in the etiologic workup, avoid the need for a muscle biopsy, and initiate and direct clinical management changes that can result in improved health outcomes. Therefore, the evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

Practice Guidelines and Position Statements
In a report from the 171st European Neuromuscular Centre International Workshop Standards of Care and Management of FSHD held in January 2010, it is stated that when a physician concludes facioscapulohumeral syndrome based on clinical findings, the odds are in favor of FSHD, and genetic testing is the preferred diagnostic choice. (14)

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

References


### Coding

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>81404</td>
<td>Molecular pathology procedure, Level 5 (e.g., analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)</td>
</tr>
</tbody>
</table>

### Appendix

N/A

### History

<table>
<thead>
<tr>
<th>Date</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/14/13</td>
<td>New Policy. New policy developed with review of the literature through June 2013. Genetic testing for facioscapulohumeral muscular dystrophy may be considered medically necessary to confirm a diagnosis in a patient with clinical signs of the disease, but is considered investigational for all other indications.</td>
</tr>
</tbody>
</table>

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2015 Premera All Rights Reserved.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
- Civil Rights Coordinator - Complaints and Appeals
  PO Box 91102, Seattle, WA 98111
  Toll free 855-332-4535, Fax 425-918-5592; TTY 800-842-5357
  Email AppealsDepartmentInquiries@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at:
https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
- U.S. Department of Health and Human Services
  200 Independence Avenue SW, Room 509F, HHH Building
  Washington, D.C. 20201, 1–800–368–1019, 800–537–7697 (TDD)


Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost.


Oromo (Cushite):

Français (French):

Kreyòl ayisyen (Creole):

Deutsche (German):

Hmoob (Hmong):

Illoko (Illicano):
Daytoy a Pakdaara ket naglaan iti Napateg nga Impomarn. Daytoy a pakdaara mabalina nga adda ket naglaan iti napateg nga impomarn maipangepp iti aplikasyonno wens covrage babaen iti Premera Blue Cross. Daytoy ket mabalina dagiti importante a pelta iti daytoy a pakdaara. Mabalina nga adda rumbenga a gen aramidenn nga adda sakkby dagiti partikular a na litudning nga adaw tapno mapagatanley niyoo covrage ti salay-ayo wens tulong kadagiti gastos. Adda karbenganyo a mangala iti daytoy nga impomarn ken tulong iti bukodyo a pagasao nga awan ti bayadangyo. Tumawgi iti numero nga 800–722–1471 (TTY: 800–842–5357).

Italiano (Italian):

中文 (Chinese):
Premera Blue Cross. Maaðring may mga mahalagang petsa dito sa paunawa. Maaring may mga mahalagang petsa dito sa paunawa. Maaring may mga mahalagang petsa dito sa paunawa.

800-722-1471 (TTY: 800-842-5357)

Tagalog (Tagalog):
Ang Paunawa na ito ay naglalarawan ng mahalagang impormasyon. Ang paunawa na ito ay mag-aaral ng impormasyon ng Premera Blue Cross. Maaaring may mga mahalagang petsa dito sa paunawa. Maaring may mga mahalagang petsa dito sa paunawa. Maaring may mga mahalagang petsa dito sa paunawa.

800-722-1471 (TTY: 800-842-5357)

Thai (Thailand);
ประกาศข่าวสารดังกล่าว ประกาศข่าวสารที่เกี่ยวกับการบริการสุขภาพของ Premera Blue Cross และสิทธิของผู้ประสบภัยในกรณีที่คุณจะได้รับการค้ำประกันในกรณีที่มีการข้างต้นที่มีการตกลงในการสั่งซื้อสิทธิ์ในกรณีการค้ำประกันของคุณโดยไม่ได้มีการจ่ายเงินสู่ Premera Blue Cross.

800-722-1471 (TTY: 800-842-5357)

Polski (Polish):

800-722-1471 (TTY: 800-842-5357)

Português (Portuguese):
Este aviso contém informações importantes. Este aviso poderá conter informações importantes a respeito de sua aplicação ou cobertura por meio do Premera Blue Cross. Poderão existir dados importantes neste aviso.

800-722-1471 (TTY: 800-842-5357)

Română (Romanian):

Русский (Russian):
Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется принять меры к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357).

Español (Spanish):
Este Aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud o cobertura a través de Premera Blue Cross. Es posible que haya fechas clave en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357).

Тагалиш (Tagalog):
Ang Paunawa na ito ay naglalarawan ng mahalagang impormasyon. Ang paunawa na ito ay mag-aaral ng impormasyon ng Premera Blue Cross. Maaaring may mga mahalagang petsa dito sa paunawa. Maaring may mga mahalagang petsa dito sa paunawa. Maaring may mga mahalagang petsa dito sa paunawa.

800-722-1471 (TTY: 800-842-5357)

Українська (Ukrainian):
Це повідомлення містить важливу інформацію. Це повідомлення може містити важливу інформацію про Ваше звернення щодо страховального покриття через Premera Blue Cross. Зверніть увагу на ключові дати, які можуть бути вказані у цьому повідомленні. Існує імовірність того, що Вам треба буде здійснити певні кроки у конкретні кінцеві строки для того, щоб зберегти Ваше медичне страхування або отримати фінансову допомогу. У Вас є право на отримання цієї інформації та допомоги безкоштовно на Вашій рідній мові. Дозвоніться за номером телефону 800-722-1471 (TTY: 800-842-5357).